EPS Revision Screener Picks Surge: FWRD +24%, AEHR +23%, LITE +16%
The EPS revision screener flagged five stocks that rallied sharply after analysts raised forward earnings estimates. Forward Air (FWRD) gained 24.0% after its EPS growth estimate rose from 69.4% to 78.0%, Aehr Test Systems (AEHR) jumped 22.8% after a 20.0 percentage point revision and analyst upgrades citing AI demand, and Lumentum (LITE) rose 16.2% after Barclays upgraded the stock on AI networking strength. Smaller movers RCEL (+21.1%) and AIRS (+14.8%) also benefited from upward estimate revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FWRD | Industrials | 2026-07-14 | +8.6pp | +24.0% |
| AEHR | Technology | 2026-07-17 | +20.0pp | +22.8% |
| RCEL | Healthcare | 2026-07-14 | N/A | +21.1% |
| LITE | Technology | 2026-07-17 | N/A | +16.2% |
| AIRS | Healthcare | 2026-07-14 | +5.2pp | +14.8% |
Why did FWRD stock jump in July 2026?
FWRD jumped 24.0% (from $12.79 to $15.86) after analysts raised its forward EPS growth estimate from 69.4% to 78.0% on July 14.
The screener captured the revision early in the asset-light transportation company's consolidation phase. News of Forward Air's upcoming Q2 earnings release on August 5 reinforced investor confidence, and the stock extended gains through July 22.
FWRD EPS revision history → · Screener snapshot from 2026-07-14 →
FAQ: FWRD
Why did FWRD stock jump in July 2026?
FWRD surged 24.0% after analysts boosted its forward EPS growth estimate from 69.4% to 78.0% on July 14, reflecting stronger earnings expectations.
Is FWRD a buy after the rally?
The EPS revision and solid sector momentum suggest continued upside, but investors should monitor the August 5 earnings release for confirmation.
What is FWRD's EPS growth estimate?
Forward Air's forward EPS growth estimate was revised to 78.0%, up from 69.4%, a gain of 8.6 percentage points.
Why did AEHR stock jump in July 2026?
AEHR jumped 22.8% (from $81.05 to $99.50) after analysts raised its forward EPS growth estimate from 99.6% to 119.6% on July 17.
Multiple analysts upgraded the stock, citing AI-driven semiconductor testing demand and raising price targets to $110. The friction of expanding data center and advanced test needs provided a clear catalyst for the estimate revision.
AEHR EPS revision history → · Screener snapshot from 2026-07-17 →
FAQ: AEHR
Why did AEHR stock jump in July 2026?
AEHR surged 22.8% after its forward EPS growth estimate was raised from 99.6% to 119.6%, supported by analyst upgrades and bullish AI demand outlook.
What caused AEHR's surge?
Freedom Broker upgraded AEHR to Buy with a $110 target, and Craig-Hallum and Lakestreet also raised targets on AI-driven semiconductor testing growth.
What is AEHR's EPS growth estimate?
Aehr Test Systems' forward EPS growth estimate stands at 119.6%, up from 99.6% after a 20.0 percentage point revision.
Why did RCEL stock jump in July 2026?
RCEL jumped 21.1% (from $4.02 to $4.87) after analysts raised its forward EPS growth estimate to 48.4% on July 14.
The healthcare stock benefited from the upward revision ahead of its Q2 earnings release scheduled for August 6. AVITA Medical's therapeutic wound care market position and the estimate improvement drove the rally.
RCEL EPS revision history → · Screener snapshot from 2026-07-14 →
FAQ: RCEL
Why did RCEL stock jump in July 2026?
RCEL gained 21.1% after analysts revised its forward EPS growth estimate to 48.4%, with momentum building before its Q2 earnings report.
Is RCEL a buy after the rally?
The EPS revision signals improving earnings power, but the stock remains volatile; the August 6 earnings call will be a key test.
What is RCEL's EPS growth estimate?
AVITA Medical's forward EPS growth estimate is 48.4%, indicating strong expected earnings expansion next year.
Why did LITE stock jump in July 2026?
LITE jumped 16.2% (from $732.82 to $851.53) after analysts raised its forward EPS growth estimate to 125.2% on July 17.
Barclays upgraded the stock to Overweight, citing improving confidence in AI networking component demand and strong earnings potential. The screener captured the revision just before the upgrade, which served as a reinforcing catalyst.
LITE EPS revision history → · Screener snapshot from 2026-07-17 →
FAQ: LITE
Why did LITE stock jump in July 2026?
LITE rose 16.2% after its forward EPS growth estimate was raised to 125.2%, followed by a Barclays upgrade to Overweight on AI networking strength.
What caused LITE's surge?
Barclays upgraded Lumentum and raised its price target to $1,000, citing strong AI networking fundamentals and a favorable risk/reward after a pullback.
What is LITE's EPS growth estimate?
Lumentum's forward EPS growth estimate is 125.2%, reflecting robust earnings expectations tied to AI infrastructure spending.
Why did AIRS stock jump in July 2026?
AIRS jumped 14.8% (from $4.20 to $4.82) after analysts raised its forward EPS growth estimate from 44.8% to 50.0% on July 14.
No specific news accompanied the move, but the healthcare stock's estimate revision alone drove the price gain as the market priced in improved earnings momentum.
AIRS EPS revision history → · Screener snapshot from 2026-07-14 →
FAQ: AIRS
Why did AIRS stock jump in July 2026?
AIRS gained 14.8% after its forward EPS growth estimate was revised upward from 44.8% to 50.0% on July 14.
Is AIRS a buy after the rally?
The estimate revision is a positive signal, but the lack of news catalysts means investors should watch for further confirmation from earnings or guidance.
What is AIRS's EPS growth estimate?
Airsculpt Technologies' forward EPS growth estimate is 50.0%, up from 44.8%, a 5.2 percentage point increase.
Today's performers reinforce that upward EPS estimate revisions—especially when coupled with sector tailwinds like AI and analyst upgrades—can generate strong short-term price momentum. The screener's ability to capture these revisions early continues to identify mispriced opportunities in both large-cap tech and smaller industrials/healthcare names.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →